Targeted Therapy & Precision Oncology
Part of Healthcare - Oncology
 LLY | Eli Lilly & Co. | $1.0t | $1191.00 | +1.8% | 2.3M |
 RVMD | Revolution Medicines, Inc. Common Stock | $38.8b | $199.45 | +0.3% | 1.5M |
 INCY | Incyte Genomics Inc | $24.2b | $119.00 | -1.2% | 2.0M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.9b | $254.00 | -1.9% | 575.7K |
 EXEL | Exelixis Inc | $13.3b | $52.35 | -7.9% | 4.2M |
 CORT | Corcept Therapeutics Inc. | $12.4b | $106.93 | -2.5% | 616.0K |
 HALO | Halozyme Therapeutics, Inc. | $9.8b | $90.15 | +2.7% | 2.1M |
 NUVL | Nuvalent, Inc. Class A Common Stock | $9.8b | $123.96 | 0.0% | N/A |
 COGT | Cogent Biosciences, Inc. Common Stock | $6.7b | $42.13 | -1.1% | 803.7K |
 ERAS | Erasca, Inc. Common Stock | $6.3b | $18.30 | -1.9% | 2.1M |
 TNGX | Tango Therapeutics, Inc. | $4.4b | $28.25 | +0.7% | 1.1M |
 CELC | Celcuity Inc. Common Stock | $4.2b | $94.44 | +0.4% | 427.1K |
 RLAY | Relay Therapeutics, Inc. Common Stock | $4.1b | $19.59 | +0.1% | 1.9M |
 ELVN | Enliven Therapeutics, Inc. Common Stock | $3.8b | $63.39 | +1.0% | 1.4M |
 IDYA | IDEAYA Biosciences, Inc. Common Stock | $3.4b | $36.34 | +0.5% | 352.1K |
 IMNM | Immunome, Inc. | $2.6b | $25.82 | +1.4% | 679.5K |
 NRIX | Nurix Therapeutics, Inc. Common stock | $2.4b | $24.93 | +0.4% | 410.5K |
 DAWN | Day One Biopharmaceuticals, Inc. Common Stock | $2.2b | $21.52 | -0.0% | 3.0M |
 NUVB | Nuvation Bio Inc. | $2.1b | $6.12 | -4.1% | 7.8M |
 BHVN | Biohaven Ltd. | $2.0b | $14.48 | +5.8% | 1.6M |
 TYRA | Tyra Biosciences, Inc. Common Stock | $1.9b | $27.50 | +4.9% | 680.4K |
 URGN | UroGen Pharma Ltd. Ordinary Shares | $1.9b | $45.87 | -1.7% | 1.0M |
 DMRA | Damora Therapeutics, Inc. Ordinary Shares | $1.8b | $29.89 | -3.1% | 626.6K |
 NVCR | NovoCure Limited Ordinary Shares | $1.8b | $16.10 | -2.2% | 757.7K |
 ZYME | Zymeworks Inc. | $1.6b | $23.14 | -1.4% | 455.3K |
 VIR | Vir Biotechnology, Inc. Common Stock | $1.5b | $8.81 | -3.7% | 2.3M |
 GLUE | Monte Rosa Therapeutics, Inc. Common Stock | $1.4b | $16.02 | +0.8% | 869.0K |
 AVBP | ArriVent BioPharma, Inc. Common Stock | $1.4b | $31.07 | +1.4% | 134.4K |
 ORIC | Oric Pharmaceuticals, Inc. Common Stock | $1.1b | $12.93 | -0.2% | 724.6K |
 OLMA | Olema Pharmaceuticals, Inc. Common Stock | $1.0b | $11.79 | +1.9% | 612.2K |
 GERN | Geron Corp | $0.8b | $1.56 | -4.3% | 15.0M |
 KURA | Kura Oncology, Inc. | $0.8b | $9.29 | +0.9% | 660.3K |
 MNPR | Monopar Therapeutics Inc. Common Stock | $0.7b | $120.43 | +0.7% | 268.9K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.7b | $38.73 | -3.3% | 292.3K |
 NVCT | Nuvectis Pharma, Inc. Common Stock | $0.7b | $18.86 | -2.3% | 178.6K |
 BBOT | BridgeBio Oncology Therapeutics, Inc. Common Stock | $0.6b | $8.81 | -2.1% | 165.5K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.6b | $5.07 | -1.3% | 781.2K |
 ARVN | Arvinas, Inc | $0.5b | $8.45 | +3.3% | 2.3M |
 VSTM | Verastem, Inc. | $0.5b | $6.29 | +12.3% | 1.6M |
 DCTH | Delcath Systems Inc | $421.9m | $15.19 | +22.6% | 2.9M |
 STRO | Sutro Biopharma, Inc. | $415.9m | $24.13 | -4.3% | 131.8K |
 PBYI | PUMA BIOTECHNOLOGY INC | $391.4m | $8.29 | +1.8% | 394.8K |
 CCCC | C4 Therapeutics, Inc. | $384.8m | $3.69 | +0.7% | 1.5M |
 PRLD | Prelude Therapeutics Incorporated | $349.6m | $4.67 | +2.8% | 181.3K |
 ZNTL | Zentalis Pharmaceuticals, Inc. Common Stock | $331.0m | $4.80 | +0.8% | 642.1K |
 TLSI | TriSalus Life Sciences, Inc. Common Stock | $291.7m | $4.82 | +4.8% | 179.7K |
 IMRX | Immuneering Corporation Class A Common Stock | $267.2m | $4.51 | +1.6% | 706.0K |
 WHWK | Whitehawk Therapeutics, Inc. Common Stock | $195.8m | $4.57 | +15.2% | 290.4K |
 PYXS | Pyxis Oncology, Inc. Common Stock | $192.6m | $3.72 | +19.8% | 1.2M |
 CRBP | Corbus Pharmaceuticals Holdings, Inc. | $166.2m | $9.71 | +1.9% | 143.6K |